Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence
DOI 10.1037/1064-1297.13.4.293
Marsch, L. A.; Stephens, M. A. C.; Mudric, T.; Strain, E. C.; Bigelow, G. E.; Johnson, R. E. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence Exp. Clin. Psychopharmacol. 2005, 13, 293-302 (Pubitemid 43011154)
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent
Cowan, A.; Lewis, J. W.; Macfarlane, I. R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent Br. J. Pharmacol. 1997b, 60, 537-545
Reinforcing Effects, Discriminative Stimulus Effects and Physical Dependence Liability of Buprenorphine
In; Cowan, A. Lewis, J. W. Wiley-Liss: New York
Negus, S. S.; Woods, J. H. Reinforcing Effects, Discriminative Stimulus Effects and Physical Dependence Liability of Buprenorphine. In Buprenorphine: Combating Drug Abuse with a Unique Opioid; Cowan, A.; Lewis, J. W., Eds.; Wiley-Liss: New York, 1995; pp 71-101.
Update on the General Pharmacology of Buprenorphine
In; Cowan, A. Lewis, J. W. Wiley-Liss: New York
Cowan, A. Update on the General Pharmacology of Buprenorphine. In Buprenorphine: Combating Drug Abuse with a Unique Opioid; Cowan, A.; Lewis, J. W., Eds.; Wiley-Liss: New York, 1995; pp 31-47.
In; Budd, K. Raffa, R. Thieme Medical Publishers: New York.
Cowan, A.; Friderichs, E.; Strasburger, W.; Raffa, R. B. Basic Pharmacology of Buprenorphine. In Buprenorphine: The Unique Opioid Analgesic; Budd, K.; Raffa, R., Eds.; Thieme Medical Publishers: New York, 2005.
Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors
DOI 10.1016/S0014-2999(01)01282-1, PII S0014299901012821
Zaveri, N.; Polgar, W. E.; Olsen, C. M.; Kelson, A. B.; Grundt, P.; Lewis, J. W.; Toll, L. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors Eur. J. Pharmacol. 2001, 428, 29-36 (Pubitemid 32971754)
Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor
Bloms-Funke, P.; Gillen, C.; Schuettler, A. J.; Wnendt, S. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor Peptides 2000, 21, 1141-1146
Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist
Huang, P.; Kehner, G. B.; Cowan, A.; Liu-Chen, L. Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist J. Pharmacol. Exp. Ther. 2001, 297, 688-695 (Pubitemid 32378001)
Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors
Lutfy, K.; Eitan, S.; Bryant, C. D.; Yang, Y. C.; Saliminejad, N.; Walwyn, W.; Kieffer, B. L.; Takeshima, H.; Carroll, F. I.; Maidment, N. T.; Evans, C. J. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors J. Neurosci. 2003, 23, 10331-10337 (Pubitemid 37444610)
In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions
Dum, J. E.; Herz, A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions Br. J. Pharmacol. 1981, 74, 627-633 (Pubitemid 12239832)
Modification of Nociception and Morphine Tolerance by the Selective Opiate Receptor-Like Orphan Receptor Antagonist (-)-cis-1-Methyl-7-[[4-(2,6- dichlorophenyl)piperidin-1-yl]methyl]-6,7,8, 9-tetrahydro-5H-benzocyclohepten-5- ol (SB-612111)
DOI 10.1124/jpet.103.055848
Zaratin, P. F.; Petrone, G.; Sbacchi, M.; Garnier, M.; Fossati, C.; Petrillo, P.; Ronzoni, S.; Giardina, G. A.; Scheideler, M. A. Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl] methyl]- 6,7,8,9- tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) J. Pharmacol. Exp. Ther. 2004, 308, 454-461 (Pubitemid 38134204)
In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist
DOI 10.1016/S0014-2999(00)00520-3, PII S0014299900005203
Ozaki, S.; Kawamoto, H.; Itoh, Y.; Miyaji, M.; Azuma, T.; Ichikawa, D.; Nambu, H.; Iguchi, T.; Iwasawa, Y.; Ohta, H. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist Eur. J. Pharmacol. 2000, 402, 45-53 (Pubitemid 30625309)
2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1- pyrrolidinyl)ethyl]acetamide: An opioid receptor affinity label that produces selective and long-lasting κ antagonism in mice
DOI 10.1021/jm00037a001
Chang, A.-C.; Takemori, A. E.; Portoghese, P. S. 2-(3,4-dichlorophenyl)- N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid recptor affinity label that produces selective and long-lasting κ antagonism in mice J. Med. Chem. 1994, 37, 1547-1549 (Pubitemid 24195465)
Opioid ligands having delayed long-term antagonist activity: Potential pharmacotherapies for opioid abuse
Husbands, S. M.; Lewis, J. W. Opioid ligands having delayed long-term antagonist activity: Potential pharmacotherapies for opioid abuse Mini-Rev. Med. Chem. 2003, 3, 137-144
Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism
Jiang, Q.; Seyed-Mozaffari, A.; Sebastian, A.; Archer, S.; Bidlack, J. M. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism J. Pharmacol. Exp. Ther. 1995, 273, 680-688
Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: In vivo and in vitro characterization of μ-selective agonist and antagonist activity
McLaughlin, J. P.; Hill, K. P.; Jiang, Q.; Sebastian, A.; Archer, S.; Bidlack, J. M. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of μ-selective agonist and antagonist activity J. Pharmacol. Exp. Ther. 1999, 289, 304-311 (Pubitemid 29156043)
Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP
Zaveri, N.; Jiang, F.; Olsen, C.; Polgar, W.; Toll, L. Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): ligand-based analysis of structural factors influencing intrinsic activity at NOP AAPS J. 2005, 7, E345-352
A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: Anxiolytic profile in the rat
DOI 10.1073/pnas.090514397
Jenck, F.; Wichmann, J.; Dautzenberg, F. M.; Moreau, J.-L.; Ouagazzal, A. M.; Martin, J. R.; Lundstrom, K.; Cesura, A. M.; Poli, S. M.; Roever, S.; Kolczewski, S.; Adam, G.; Kilpatrick, G. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4938-4943 (Pubitemid 30238661)
Decoration of the aromatic ring of dihydrocodeinone (hydrocodone) and 14-hydroxydihydrocodeinone (oxycodone)
DOI 10.1021/jo050264+
Wilson, M. L.; Carroll, P. J.; Dalton, D. R. Decoration of the aromatic ring of dihydrocodeinone (hydrocodone) and 14-hydroxydihydrocodeinone (oxycodone) J. Org. Chem. 2005, 6492-6495 (Pubitemid 41076535)
Synthesis of iodobuprenorphine for use in radioimmunoassay
Debrabandere, L.; Vanboven, M.; Daenens, P. Synthesis of iodobuprenorphine for use in radioimmunoassay J. Labelled Compd. Radiopharm. 1992, 31, 575-588
Novel analgesics and molecular rearrangements in the morphine-thebaine group. VI. Base-catalyzed rearrangements in the 6,14-endo- ethenotetrahydrothebaine series
Bentley, K. W.; Hardy, D. G.; Crocker, H. P.; Haddlesey, D. I.; Mayor, P. A. Novel analgesics and molecular rearrangements in the morphine-thebaine group. VI. Base-catalyzed rearrangements in the 6,14-endo- ethenotetrahydrothebaine series J. Am. Chem. Soc. 1967, 89, 3312-3321
Activities of mixed NOP and μ-opioid receptor ligands
DOI 10.1038/sj.bjp.0707598, PII 0707598
Spagnolo, B.; Calo, G.; Polgar, W. E.; Jiang, F.; Olsen, C. M.; Berzetei-Gurske, I.; Khroyan, T. V.; Husbands, S. M.; Lewis, J. W.; Toll, L.; Zaveri, N. T. Activities of mixed NOP and mu-opioid receptor ligands Br. J. Pharmacol. 2008, 153, 609-619 (Pubitemid 351199024)
Lewis, J. W. Buprenorphine: Medicinal Chemistry. In Buprenorphine: Combating Drug Abuse with a Unique Opioid; Cowan, A.; Lewis, J. W., Eds.; Wiley-Liss: New York, 1995; pp 3-16.
Structural determinants of efficacy for κ opioid receptors in the orvinol series: 7,7-Spiro analogues of buprenorphine [1]
DOI 10.1021/jm991165p
Husbands, S. M.; Lewis, J. W. Structural determinants of efficacy for κ-opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine J. Med. Chem. 2000, 43, 139-141 (Pubitemid 30078144)
The orvinols and related opioids - High affinity ligands with diverse efficacy profiles
DOI 10.2174/1381612043453027
Lewis, J. W.; Husbands, S. M. The orvinols and related opioids: high affinity ligands with diverse efficacy profiles Curr. Pharm. Des. 2004, 10, 717-732 (Pubitemid 38292400)
The first 'universal opioid ligand' (2S)-2-[(5R,6R,7R,14S)-N- cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3, 3-dimethylpentan-2-ol (BU08028): Characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward
Khroyan, T. V.; Polgar, W. E.; Cami-Kobeci, G.; Husbands, S. M.; Zaveri, N. T.; Toll, L. The first 'universal opioid ligand' (2S)-2-[(5R,6R,7R,14S)-N- cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3, 3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward J. Pharmacol. Exp. Ther. 2011, 336, 952-961
